adenosine diphosphate has been researched along with Cancer of Ovary in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (18.52) | 24.3611 |
| 2020's | 21 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, Z; Zhang, J; Zhang, Z | 1 |
| Cho, YJ; Choi, JJ; Choi, JY; Hwang, JR; Jeong, SY; Lee, JW; Ryu, JY; Sa, JK; Shim, JI | 1 |
| Arenare, L; Baldassarre, G; Bartoletti, M; Califano, D; Capoluongo, E; Chiodini, P; Costi, MP; D'Incalci, M; Greggi, S; Marchini, S; Mezzanzanica, D; Musacchio, L; Normanno, N; Perrone, F; Pignata, S; Scala, S; Schettino, C | 1 |
| Cao, L; Li, Y; Wang, J; Yu, X; Zhang, M | 1 |
| Alexandrov, LB; Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Choi, J; Clark, M; Harold, J; Hartwich, TMP; Huang, GS; Jeong, K; Manara, P; Manavella, DD; Menderes, G; Mutlu, L; Ratner, E; Santin, AD; Schwartz, PE; Tymon-Rosario, JR; Yang, K; Yang-Hartwich, Y; Zipponi, M | 1 |
| Hirata, M; Ishikawa, M; Noguchi, E; Odaka, Y; Saito, A; Shimoi, T; Sudo, K; Tanioka, M; Watanabe, T; Yonemori, K | 1 |
| Aryal, N; Asher, R; Berton, D; Colombo, N; Freimund, AE; Frenel, JS; Huzarski, T; Kim, JW; Korach, J; Ledermann, JA; Lee, CK; Oza, AM; Park-Simon, TW; Pautier, P; Penson, RT; Pignata, S; Pujade-Lauraine, E; Sonke, GS; Tamura, K; Vidal, L | 1 |
| Bernard, J; Douville, P; Gregoire, J; Langlais, EL; Mehros, W; Plante, M; Renaud, MC; Sebastianelli, A | 1 |
| Ansell, PJ; Bell-McGuinn, K; Bookman, MA; Coleman, RL; Dinh, MH; Fleming, GF; Friedlander, M; Hosmane, B; Huang, X; Luo, X; Moore, KN; Sehgal, V; Steffensen, KD; Swisher, EM; You, B | 1 |
| Fiteni, F; Peron, J | 1 |
| Lu, W; Shen, Y; Shen, Z; Tang, S; Wei, X; Xu, J | 1 |
| Beijnen, JH; Bruin, MAC; Huitema, ADR; Sonke, GS | 1 |
| Arend, R; Ethier, JL; Fuh, KC; Kohn, EC; Konecny, GE; Konstantinopoulos, PA; Odunsi, K; Swisher, EM; Zamarin, D | 1 |
| Compton, K; Karsan, A; Kwon, JS; Santos, J; Schrader, KA; Sun, S; Tinker, AV | 1 |
| Bose, S; Huang, Q; Kontos, CD; Previs, RA; Shen, X; Whitaker, R; Yao, H | 1 |
| Chu, YY; Hung, MC; Yam, C; Yamaguchi, H | 1 |
| Moore, KN; Washington, CR | 1 |
| Guo, J; Li, X; Shi, J; Wang, R; Wen, L; Yao, M; Zhang, S | 1 |
| Li, Y; Liu, CF; Rao, GW | 1 |
| Chelariu-Raicu, A; Hinchcliff, E; Westin, SN | 1 |
| Cheng, H; Liu, H; Xiang, Y; Yang, J | 1 |
| Konecny, GE | 1 |
| Afshar-Kharghan, V; Armaiz-Pena, GN; Bottsford-Miller, J; Burns, AR; Cho, MS; Choi, HJ; Dalton, HJ; Gharpure, KM; Gutschner, T; Haemmerle, M; Han, HD; Hansen, JM; Lopez-Berestein, G; Mangala, LS; Nagaraja, AS; Nick, AM; Pecot, CV; Pradeep, S; Rupaimoole, R; Sood, AK; Stone, RL; Taylor, ML; Wu, SY; Zand, B | 1 |
| Afshar-Kharghan, V; Feng, S; Kroll, MH; Nick, AM; Sood, AK | 1 |
| Curiel, TJ; Fan, J; Shin, T; Thompson, LF; Wang, L; Zhang, B; Zhang, Y | 1 |
| Berndt, M; Canney, A; Conlon, N; Crowley, D; Ducrée, J; Dunne, E; Egan, K; Ffrench, B; Finn, S; Gallagher, M; Keegan, H; Kenny, D; Laios, A; Martin, C; McEneaney, V; McEvoy, L; Norris, L; O'Leary, J; O'Toole, S; Sheils, O; Smith, L; Smyth, P; Spillane, C; Stordal, B | 1 |
| Kozyreva, EV; Mitiushin, VM | 1 |
9 review(s) available for adenosine diphosphate and Cancer of Ovary
| Article | Year |
|---|---|
Correlation of poly (adenosine diphosphate[ADP]-ribose) polymerase expression and prognosis in ovarian cancer: A systematic review and meta-analysis.
Topics: Adenosine Diphosphate; Adenosine Diphosphate Ribose; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Ribose | 2022 |
Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Topics: Adenosine Diphosphate; Breast Neoplasms; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Ribose | 2021 |
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Topics: Adenosine Diphosphate; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose | 2022 |
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Topics: Adenosine Diphosphate; Biomarkers; BRCA1 Protein; DNA; Female; Humans; Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
Topics: Adenosine Diphosphate; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Female; Humans; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose | 2021 |
Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
Topics: Adenosine Diphosphate; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose | 2021 |
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Treatment Outcome | 2021 |
[Several types of mitochondrial ultrastructure in animal cell mitochondria and their relationship to energy production].
Topics: Adenosine Diphosphate; Animals; Energy Metabolism; Female; In Vitro Techniques; Mesenchymoma; Microscopy, Electron; Mitochondria; Mitochondria, Liver; Neoplasms, Experimental; Ovarian Neoplasms; Oxidative Phosphorylation; Oxygen Consumption; Rabbits; Thiourea | 1978 |
1 trial(s) available for adenosine diphosphate and Cancer of Ovary
| Article | Year |
|---|---|
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Topics: Adenosine Diphosphate; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease Progression; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
17 other study(ies) available for adenosine diphosphate and Cancer of Ovary
| Article | Year |
|---|---|
Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; DNA; Female; Humans; Ovarian Neoplasms; Phthalazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Xenograft Model Antitumor Assays | 2022 |
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Mangifera; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Topics: Adenosine Diphosphate; Animals; Carcinosarcoma; Cell Line, Tumor; Female; Homologous Recombination; Humans; Ovarian Neoplasms; Ovary; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose | 2022 |
Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
Topics: Adenosine Diphosphate; Aged; BRCA1 Protein; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Topics: Adenosine Diphosphate; BRCA1 Protein; BRCA2 Protein; Canada; Carcinoma; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA2; Genetic Predisposition to Disease; Germ Cells; Germ-Line Mutation; Humans; Mismatch Repair Endonuclease PMS2; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Ribose | 2022 |
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
Topics: Adenosine Diphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Ribose | 2023 |
Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective.
Topics: Adenosine Diphosphate; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; Ribose | 2022 |
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Topics: Adenosine Diphosphate; AMP-Activated Protein Kinases; Animals; Apoptosis; Arsenic Trioxide; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Ferroptosis; Humans; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose; Stearoyl-CoA Desaturase | 2022 |
State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Biomarkers; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; National Cancer Institute (U.S.); Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Tumor Microenvironment; United States | 2022 |
Germline Testing and Somatic Tumor Testing for
Topics: Adenosine Diphosphate; Aged; Antineoplastic Agents; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Medicare; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; United States | 2022 |
Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Biosensing Techniques; Carboplatin; Carcinoma, Ovarian Epithelial; Culture Media, Conditioned; Female; Humans; NAD; NADP; Ovarian Neoplasms; Tumor Microenvironment | 2022 |
Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of
Topics: Adenosine Diphosphate; Alleles; BRCA1 Protein; Breast Neoplasms; Enzyme Inhibitors; Female; Genes, BRCA2; Germ Cells; Humans; Male; Middle Aged; Ovarian Neoplasms; Ribose; Stomach Neoplasms | 2020 |
Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
Topics: Adenosine Diphosphate; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerases; Ribose | 2017 |
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Topics: Adenosine Diphosphate; Animals; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Platelets; Cell Hypoxia; Cell Line, Tumor; Female; Focal Adhesion Kinase 1; Humans; Indazoles; Mice; Mice, Knockout; Neoplasm Proteins; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Platelets are not hyperreactive in patients with ovarian cancer.
Topics: Adenosine Diphosphate; Blood Platelets; Collagen; Female; Humans; Ovarian Neoplasms; Platelet Activation; Platelet Aggregation; Platelet Count; Thrombocytosis | 2016 |
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Animals; Chemotaxis, Leukocyte; Disease Progression; Female; Immunotherapy, Adoptive; Lymphocytes, Tumor-Infiltrating; Lymphoma, Non-Hodgkin; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Molecular Targeted Therapy; Ovarian Neoplasms; Peritoneal Neoplasms; Radiation Chimera; Second Messenger Systems; T-Lymphocytes; T-Lymphocytes, Regulatory; Tumor Burden | 2011 |
Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Apyrase; Arachidonic Acid; Cell Degranulation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Peptide Fragments; Platelet Adhesiveness; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Reproducibility of Results; Signal Transduction | 2011 |